vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and La Rosa Holdings Corp. (LRHC). Click either name above to swap in a different company.

La Rosa Holdings Corp. is the larger business by last-quarter revenue ($20.2M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -177.4%, a 150.0% gap on every dollar of revenue. On growth, La Rosa Holdings Corp. posted the faster year-over-year revenue change (3.2% vs -11.5%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

LAB vs LRHC — Head-to-Head

Bigger by revenue
LRHC
LRHC
1.0× larger
LRHC
$20.2M
$19.6M
LAB
Growing faster (revenue YoY)
LRHC
LRHC
+14.7% gap
LRHC
3.2%
-11.5%
LAB
Higher net margin
LRHC
LRHC
150.0% more per $
LRHC
-27.4%
-177.4%
LAB
Faster 2-yr revenue CAGR
LRHC
LRHC
Annualised
LRHC
72.5%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
LAB
LAB
LRHC
LRHC
Revenue
$19.6M
$20.2M
Net Profit
$-34.7M
$-5.5M
Gross Margin
48.5%
8.4%
Operating Margin
-168.5%
-24.7%
Net Margin
-177.4%
-27.4%
Revenue YoY
-11.5%
3.2%
Net Profit YoY
-28.8%
-125.7%
EPS (diluted)
$-0.09
$-5.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LRHC
LRHC
Q3 25
$19.6M
$20.2M
Q2 25
$21.8M
$23.2M
Q1 25
$40.8M
$17.5M
Q4 24
$17.7M
Q3 24
$22.1M
$19.6M
Q2 24
$22.5M
$19.1M
Q1 24
$45.5M
$13.1M
Q4 23
$28.2M
Net Profit
LAB
LAB
LRHC
LRHC
Q3 25
$-34.7M
$-5.5M
Q2 25
$-33.5M
$78.4M
Q1 25
$-26.0M
$-95.7M
Q4 24
$-5.1M
Q3 24
$-26.9M
$-2.5M
Q2 24
$-45.7M
$-2.3M
Q1 24
$-32.2M
$-4.6M
Q4 23
$-19.8M
Gross Margin
LAB
LAB
LRHC
LRHC
Q3 25
48.5%
8.4%
Q2 25
48.8%
8.0%
Q1 25
48.4%
8.8%
Q4 24
8.9%
Q3 24
54.9%
8.3%
Q2 24
46.1%
8.3%
Q1 24
53.1%
8.9%
Q4 23
47.6%
Operating Margin
LAB
LAB
LRHC
LRHC
Q3 25
-168.5%
-24.7%
Q2 25
-118.1%
-10.6%
Q1 25
-80.8%
-26.7%
Q4 24
-17.1%
Q3 24
-120.9%
-8.9%
Q2 24
-134.5%
-9.7%
Q1 24
-132.2%
-35.0%
Q4 23
-75.9%
Net Margin
LAB
LAB
LRHC
LRHC
Q3 25
-177.4%
-27.4%
Q2 25
-153.7%
337.8%
Q1 25
-63.8%
-546.5%
Q4 24
-28.7%
Q3 24
-122.0%
-12.5%
Q2 24
-203.3%
-12.2%
Q1 24
-70.6%
-35.1%
Q4 23
-70.2%
EPS (diluted)
LAB
LAB
LRHC
LRHC
Q3 25
$-0.09
$-5.44
Q2 25
$-0.09
$15.25
Q1 25
$-0.07
$-5.86
Q4 24
$28.54
Q3 24
$-0.07
$-16.49
Q2 24
$-0.12
$-12.49
Q1 24
$-0.27
$-0.35
Q4 23
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LRHC
LRHC
Cash + ST InvestmentsLiquidity on hand
$129.4M
$4.0M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$399.7M
$1.6M
Total Assets
$539.6M
$21.7M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LRHC
LRHC
Q3 25
$129.4M
$4.0M
Q2 25
$158.6M
$5.1M
Q1 25
$150.9M
$2.9M
Q4 24
$1.4M
Q3 24
$210.6M
$1.8M
Q2 24
$269.8M
$1.6M
Q1 24
$287.1M
$1.1M
Q4 23
$51.7M
Total Debt
LAB
LAB
LRHC
LRHC
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$55.2M
$649.2K
Q2 24
$55.1M
$650.8K
Q1 24
$55.0M
$652.4K
Q4 23
$63.5M
Stockholders' Equity
LAB
LAB
LRHC
LRHC
Q3 25
$399.7M
$1.6M
Q2 25
$424.5M
$3.4M
Q1 25
$454.6M
$-87.5M
Q4 24
$2.6M
Q3 24
$489.3M
$5.0M
Q2 24
$510.3M
$4.7M
Q1 24
$577.3M
$5.6M
Q4 23
$-148.1M
Total Assets
LAB
LAB
LRHC
LRHC
Q3 25
$539.6M
$21.7M
Q2 25
$557.0M
$22.9M
Q1 25
$579.6M
$21.0M
Q4 24
$19.4M
Q3 24
$681.5M
$19.7M
Q2 24
$708.7M
$18.7M
Q1 24
$777.7M
$16.3M
Q4 23
$323.1M
Debt / Equity
LAB
LAB
LRHC
LRHC
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.11×
0.13×
Q2 24
0.11×
0.14×
Q1 24
0.10×
0.12×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LRHC
LRHC
Operating Cash FlowLast quarter
$-22.2M
$-1.3M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LRHC
LRHC
Q3 25
$-22.2M
$-1.3M
Q2 25
$-20.7M
$-1.4M
Q1 25
$-30.3M
$-3.5M
Q4 24
$-1.1M
Q3 24
$-27.9M
$-591.6K
Q2 24
$-39.0M
$-803.1K
Q1 24
$-62.5M
$-538.3K
Q4 23
$-14.1M
Free Cash Flow
LAB
LAB
LRHC
LRHC
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
FCF Margin
LAB
LAB
LRHC
LRHC
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Capex Intensity
LAB
LAB
LRHC
LRHC
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Q4 23
0.3%
Cash Conversion
LAB
LAB
LRHC
LRHC
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

Related Comparisons